Last $12.41 USD
Change Today -0.2235 / -1.77%
Volume 7.4K
As of 8:10 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

ipsen sa-sponsored adr (IPSEY) Snapshot

Open
$12.71
Previous Close
$12.63
Day High
$12.71
Day Low
$12.41
52 Week High
09/22/14 - $12.71
52 Week Low
09/23/13 - $9.23
Market Cap
4.1B
Average Volume 10 Days
66.7K
EPS TTM
--
Shares Outstanding
331.1M
EX-Date
06/4/14
P/E TM
--
Dividend
$0.27
Dividend Yield
2.18%
Current Stock Chart for IPSEN SA-SPONSORED ADR (IPSEY)

Related News

No related news articles were found.

ipsen sa-sponsored adr (IPSEY) Related Businessweek News

View More BusinessWeek News

ipsen sa-sponsored adr (IPSEY) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,600 Employees
Last Reported Date: 08/29/14
Founded in 1929

ipsen sa-sponsored adr (IPSEY) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen sa-sponsored adr (IPSEY) Key Developments

Ipsen Bioscience Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Ipsen Bioscience Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Ipsen Announces Acceptance of Filings for Somatuline(R) in the Treatment of GEP-NET in the US with Priority Review and in Europe

Ipsen announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of its supplemental New Drug Application (sNDA) for Somatuline(R) Depot(R) 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA designates priority review status to drug candidates that have the potential to offer a significant improvement in treatment compared to currently approved options. Decision is expected in early first quarter of 2015. In the European Union, the dossier of the national marketing authorization (MA) variations for Somatuline(R) Autogel(R) 120mg injection has been validated by all national 25 drug regulatory authorities. The first decisions are expected by second quarter of 2015. The regulatory submissions and variations were supported by the results of the CLARINET(R) Phase III study, which demonstrated the antitumor effect of Somatuline(R) in the treatment of patients with GEP-NETs, and which was recently published in the July 17th issue of The New England Journal of Medicine. The data from CLARINET(R) is purely investigational, as Somatuline(R) is not authorized for the indication of treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in any market. In many countries where it is marketed as Somatuline(R) Autogel(R), Somatuline(R) is approved for treatment of acromegaly and for the symptoms associated with neuroendocrine tumors, which can include the treatment of GEP-NET patients experiencing symptoms from carcinoid syndrome, and Somatuline(R) is approved in many countries for the treatment of acromegaly. Somatuline(R) Depot is approved in the US for the treatment of acromegaly but not for the treatment of GEP-NETs or the symptoms thereof.

Ipsen S.A. Announces Consolidated Unaudited Earnings Results for the Six Months Ended June 30, 2014

Ipsen S.A. announced consolidated unaudited earnings results for the six months ended June 30, 2014. For the period, the company reported sales of EUR 638.7 million against EUR 633.6 million a year ago. Revenues were EUR 668.8 million against EUR 663.9 million a year ago. Core Operating Income was EUR 162.0 million against EUR 144.0 million a year ago. Operating income was EUR 146.3 million against EUR 133.1 million a year ago, notably affected by impairment losses on Increlex (IGF-1). Net profit from continuing operations was EUR 104.7 million against EUR 90.3 million a year ago. Consolidated net profit attributable to shareholders of the company was EUR 104.0 million against EUR 96.2 a year ago. Earnings per share fully diluted share were EUR 1.26 against EUR 1.15 a year ago. Core earnings per share fully diluted was EUR 1.40 against EUR 1.18 a year ago. Net cash provided by operating activities was EUR 54.7 million against EUR 54.5 million a year ago. Net investments in tangible and intangible assets were EUR 24 million against EUR 11.8 million a year ago. This cash flow mainly included: acquisition of property, plant and equipment totaling EUR 20.9 million, compared with EUR 10.9 million in the first half 2013. Acquisition of intangible assets for EUR 3.3 million, compared with EUR 1.1 million in the first half 2013, primarily related to IT. Core operating income was up 12.5%, supported by sales growth and continuous cost control.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPSEY:US $12.41 USD -0.2235

IPSEY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.16 EUR -0.13
Meda AB kr100.50 SEK -2.20
Orion OYJ €29.83 EUR -0.40
Procter & Gamble Hygiene & Health Care Ltd 4,850 INR -3.75
Recordati SpA €12.81 EUR -0.09
View Industry Companies
 

Industry Analysis

IPSEY

Industry Average

Valuation IPSEY Industry Range
Price/Earnings 19.8x
Price/Sales 2.4x
Price/Book 3.1x
Price/Cash Flow 18.8x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN SA-SPONSORED ADR, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.